Literature DB >> 11012033

Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines.

Y Okada1, Y Tsuda, K Wanaka, M Tada, U Okamoto, S Okamoto, A Hijikata-Okunomiya, G Bokonyi, B Szende, G Keri.   

Abstract

trans-4-Aminomethylcyclohexanecarbonyl-Tyr(O-Pic)-octylamide (YO-2) inhibited plasmin (PL) selectively, while trans-4-aminomethylcyclohexanecarbonyl-Phe-4-carboxymethylanili de (YO-1) inhibited plasma kallikrein (PK). YO-2 induced apoptosis of M1 (melanoma) cell line and HT29 colon carcinoma cells during 24 h through activation of caspase-3, while YO-1 did not affect either cell line even during 48 h.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012033     DOI: 10.1016/s0960-894x(00)00431-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.

Authors:  Ruby H P Law; Guojie Wu; Eleanor W W Leung; Koushi Hidaka; Adam J Quek; Tom T Caradoc-Davies; Devadharshini Jeevarajah; Paul J Conroy; Nigel M Kirby; Raymond S Norton; Yuko Tsuda; James C Whisstock
Journal:  Blood Adv       Date:  2017-05-09

Review 2.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.